CADTH | Evidence Driven
CADTH | Evidence Driven

ibrutinib

Details

Generic Name:
ibrutinib
Project Status:
Pending
Therapeutic Area:
Waldenström’s Macroglobulinemia
Manufacturer:
Janssen Inc.
Call for patient/clinician input open:
Brand Name:
Imbruvica
Project Line:
Reimbursement Review
Project Number:
PC0328-000
Call for patient/clinician input closed:
Tumour Type:
Lymphoma
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
​​Imbruvica, as a single agent or in combination with rituximab, for previously treated, relapsed/refractory (RR) Waldenström’s Macroglobulinemia (WM).
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
​Imbruvica, as a single agent or in combination with rituximab, for previously treated, relapsed/refractory (RR) Waldenström’s Macroglobulinemia (WM).
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Last Updated : May 9, 2023